Imedex® is an industry leader in providing accredited, independent continuing medical education to health care professionals.

May 30, 2015 | 6:30pm

Hilton Chicago
Chicago, Illinois, USA

The Clinical Potential of Novel Poly ADP-Ribose Polymerase Inhibitors for Improved Management of Epithelial Ovarian Cancer

This is an independent, accredited educational activity held adjunct to the ASCO Annual Meeting. This presentation is not sponsored or endorsed by ASCO.


Registration is complimentary. Please remember to bring your ASCO Badge.

Available seating will be based on room capacity. Seating is limited and pre-registration does not guarantee admission, as the room may be overbooked. Early arrival is recommended and seating will be first come first serve until capacity is met.

Hilton Chicago
North International Ballroom
720 South Michigan Avenue
Chicago, Illinois, 60605
Tel.: +1 (312) 922 44001


Bradley J. Monk, MD
University of Arizona Cancer Center-Phoenix
Creighton University School of Medicine at Dignity Health
St. Joseph’s Hospital and Medical Center
Phoenix, Arizona


Thomas J. Herzog, MD
University of Cincinnati
Cincinnati, Ohio

Ursula A. Matulonis, MD
Dana-Farber Cancer Institute
Boston, Massachusetts


Saturday, May 30, 2015

7:00 pm

Registration and Buffet Dinner

7:30 pm

Welcome and Introductions
Bradley J. Monk, MD, FACOG, FACS

7:35 pm

Pre-session Survey

7:40 pm

Testing for BRCA Germline Mutations in the Clinic and the Mechanism of Action of PARP Inhibitors
Bradley J. Monk, MD, FACOG, FACS

7:50 pm

Discussion and Q&A
Bradley J. Monk, MD, FACOG, FACS

7:55 pm

Clinical Data with PARP Inhibitors in Ovarian Cancer
Thomas J. Herzog, MD

8:10 pm

Challenging Clinical Cases: Novel PARP Inhibitors in the Clinic
Maintenance Therapy: Bradley J. Monk, MD, FACOG, FACS
Disease Recurrence: Ursula A. Matulonis, MD
Gastrointestinal Toxicity: Thomas J. Herzog, MD

8:40 pm

Ongoing Clinical Trials with PARP inhibitors in Ovarian Cancer
Ursula A. Matulonis, MD

8:55 pm

Panel Discussion: How to Integrate PARP Inhibitors into Current Treatment Paradigms?
Bradley J. Monk, MD, FACOG, FACS; Thomas J. Herzog, MD; Ursula A. Matulonis, MD

9:10 pm

Post-session Survey

9:15 pm

Summary of Key Points
Bradley J. Monk, MD, FACOG, FACS

9:20 pm


Continuing Medical Education

Imedex®, LLC is accredited by the Continuing Education Council for Continuing Medical Education to provide continuing medical education for physicians.

Imedex®, LLC designates this live educational activity for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Who Should Attend

These educational activities are designed to meet the educational needs of medical oncologists, gynecologic oncologists, oncology nurses, nurse practitioners, gynecologists, pathologists, pharmacists, researchers, and other healthcare professionals interested and/or involved in the care and treatment of patients with gynecologic cancers.


Upon completion of this educational activity, participants should be better able to:

  • Demonstrate enhanced understanding of BRCA-mutant tumors, PARP function in DNA repair, and the rationale for targeting the PARP pathway in the treatment of ovarian cancer
    • Evaluate the benefits and risks of emerging PARP inhibitors in the treatment of BRCA-deficient ovarian cancer
    • Recommend clinical trials of novel PARP inhibitors appropriately to ovarian cancer patients with unmet need
    • Identify ways to overcome the challenges in incorporating PARP inhibitors into routine practice for ovarian cancer

Symposium Location

Hilton Chicago
North International Ballroom
720 South Michigan Avenue
Chicago, Illinois, 60605
Tel.: +1 (312) 922 4400

iPad Interactive Technology

Imedex will incorporate iPad technology into this activity. Each participant will have access to an iPad that contains real-time presentation content, speaker biographies, and educational objectives. Throughout the activity, learners can use their device to answer pre/post-activity questions, vote on case discussions, and submit questions to the faculty.


The following company has provided an educational grant in support of this conference



11675 Rainwater Drive, Suite 600
Alpharetta, GA 30009, USA
Tel.: +1 (770) 751 7332
Fax: +1 (770) 751 7334